A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects
hospitalized with symptomatic acute decompensated heart failure (ADHF).